Prevalence and risk of small intestinal bacterial overgrowth in patients with rosacea: A systematic review and meta-analysis
- Authors: Khurmatullina А.R.1, Kucheryavyy Y.A.2, Andreev D.N.3, Tamrazova O.B.4, Maev I.V.3
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Ilyinskaya Hospital JSC
- Russian University of Medicine
- Peoples' Friendship University of Russia named after Patrice Lumumba
- Issue: Vol 97, No 7 (2025)
- Pages: 580-586
- Section: Reviews
- URL: https://journals.rcsi.science/0040-3660/article/view/314007
- DOI: https://doi.org/10.26442/00403660.2025.07.203297
- ID: 314007
Cite item
Full Text
Abstract
Aim. To systematize data on the prevalence and risk of small intestinal bacterial overgrowth (SIBO) in patients with rosacea.
Materials and methods. The search for studies was conducted in the MEDLINE/PubMed, EMBASE, and the Russian Science Citation Index from January 1, 1985, to April 5, 2025. The inclusion criteria were original clinical studies in English or Russian with detailed descriptive statistics describing the prevalence of SIBO in adults with rosacea. The analysis included an assessment of the SIBO prevalence, calculation of relative risk, and 95% confidence interval (CI) using a random effects model. Heterogeneity was assessed using I²-statistics, and publication bias was examined with funnel plots and Begg–Mazumdar and Egger tests.
Results. The meta-analysis included 6 studies with 801 subjects (581 subjects with rosacea, 220 controls). The overall prevalence of SIBO in patients with rosacea was 35.8% (95% CI 23.626–48.985) compared to 9.391% (95% CI 4.256–16.265) in controls. The risk of developing SIBO in patients with rosacea was 3.501 times higher (relative risk 3.50; 95% CI 1.347–9.100; p=0.012). Treatment with rifaximin (1200 mg/day for 10 days) resulted in significant improvement or remission of rosacea in 57.9% (95% CI 49.5–66.3) of patients, with the highest effectiveness (up to 85.7%) observed in those with successful eradication of SIBO.
Conclusion. The results of a systematic review and meta-analysis confirm the potential association between SIBO and rosacea and demonstrate the effectiveness of rifaximin in treating cutaneous manifestations of rosacea in these patients. It is necessary to consider SIBO diagnosis when assessing patients with rosacea, especially in resistant forms of the disease.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
А. R. Khurmatullina
Sechenov First Moscow State Medical University (Sechenov University)
Email: dna-mit8@mail.ru
ORCID iD: 0009-0000-4358-7823
стажер-исследователь каф. пропедевтики внутренних болезней и гастроэнтерологии
Russian Federation, MoscowYu. A. Kucheryavyy
Ilyinskaya Hospital JSC
Email: dna-mit8@mail.ru
ORCID iD: 0000-0001-7760-2091
канд. мед. наук, доц., зав. гастроэнтерологическим отд-нием
Russian Federation, KrasnogorskD. N. Andreev
Russian University of Medicine
Author for correspondence.
Email: dna-mit8@mail.ru
ORCID iD: 0000-0002-4007-7112
канд. мед. наук, доц., доц. каф. пропедевтики внутренних болезней и гастроэнтерологии
Russian Federation, MoscowO. B. Tamrazova
Peoples' Friendship University of Russia named after Patrice Lumumba
Email: dna-mit8@mail.ru
ORCID iD: 0000-0003-3261-6718
д-р мед. наук, проф. РАН, проф. каф. дерматовенерологии с курсом косметологии Медицинского института
Russian Federation, MoscowI. V. Maev
Russian University of Medicine
Email: dna-mit8@mail.ru
ORCID iD: 0000-0001-6114-564X
акад. РАН, д-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней и гастроэнтерологии
Russian Federation, MoscowReferences
- Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020;115(2):165-78. doi: 10.14309/ajg.0000000000000501
- Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Ивашкина Н.Ю. Синдром избыточного бактериального роста в тонкой кишке: клиническое значение, критерии диагностики и терапевтическая тактика. Инфекционные болезни: Новости. Мнения. Обучение. 2016;3:118-25 [Maev IV, Kucheryavyy YuA, Andreev DN, Ivashkina NYu. Small bowel bacterial overgrowth syndrome: clinical relevance, criteria of diagnostics and therapeutic management. Infectious diseases: News, Opinions, Training. 2016;3:118-25 (in Russian)].
- Losurdo G, Salvatore D'Abramo F, Indellicati G, et al. The Influence of Small Intestinal Bacterial Overgrowth in Digestive and Extra-Intestinal Disorders. Int J Mol Sci. 2020;21(10):3531. doi: 10.3390/ijms21103531
- Liu Chen Kiow J, Bellila R, Therrien A, et al. Predictors of Small Intestinal Bacterial Overgrowth in Symptomatic Patients Referred for Breath Testing. J Clin Med Res. 2020;12(10):655-61. doi: 10.14740/jocmr4320
- Efremova I, Maslennikov R, Poluektova E, et al. Epidemiology of small intestinal bacterial overgrowth. World J Gastroenterol. 2023;29(22):3400-41. doi: 10.3748/wjg.v29.i22.3400
- Cortez APB, Fisberg M, de Morais MB. Intestinal permeability and small intestine bacterial overgrowth in excess weight adolescents. Pediatr Obes. 2021;16(5):e12741. doi: 10.1111/ijpo.12741
- Дудукчян Д.А., Саркисян Д.К., Андреев Д.Н. Инфекция Helicobacter pylori и заболевания дерматологического профиля. Медицинский Совет. 2024;(8):43-9 [Dudukchyan DA, Sarkisyan DK, Andreev DN. Helicobacter pylori infection and dermatological diseases. Meditsinskiy sovet = Medical Council. 2024;(8):43-9 (in Russian)]. doi: 10.21518/ms2024-232
- Симаненков В.И., Маев И.В., Ткачева О.Н., и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20(1):2758 [Simanenkov VI, Maev IV, Tkacheva ON, et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758 (in Russian)]. doi: 10.15829/1728-8800-2021-2758
- Korsing S, Stieler K, Pleyer U, et al. Rosacea in childhood and adolescence: A review. J Dtsch Dermatol Ges. 2025. doi: 10.1111/ddg.15693
- Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018;179(2):282-8. doi: 10.1111/bjd.16481
- Sharma A, Kroumpouzos G, Kassir M, et al. Rosacea management: A comprehensive review. J Cosmet Dermatol. 2022;21(5):1895-904. doi: 10.1111/jocd.14816
- Dall'Oglio F, Fusto C, Micali G. Intrafamilial Transmission of Rosacea Spanning Six Generations: A Retrospective Observational Study. J Clin Aesthet Dermatol. 2022;15(2):35-9.
- Deng Z, Chen M, Zhao Z, et al. Whole genome sequencing identifies genetic variants associated with neurogenic inflammation in rosacea. Nat Commun. 2023;14(1):3958. doi: 10.1038/s41467-023-39761-2
- Chen C, Wang P, Zhang L, et al. Exploring the Pathogenesis and Mechanism-Targeted Treatments of Rosacea: Previous Understanding and Updates. Biomedicines. 2023;11(8):2153. doi: 10.3390/biomedicines11082153
- Nguyen C, Kuceki G, Birdsall M, et al. Rosacea: Practical Guidance and Challenges for Clinical Management. Clin Cosmet Investig Dermatol. 2024;17:175-90. doi: 10.2147/CCID.S391705
- Egeberg A, Weinstock LB, Thyssen EP, et al. Rosacea and gastrointestinal disorders: a population-based cohort study. Br J Dermatol. 2017;176(1):100. doi: 10.1111/bjd.14930
- Gravina A, Federico A, Ruocco E, et al. Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea. United European Gastroenterol J. 2015;3(1):17-24. doi: 10.1177/2050640614559262
- Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol. 2008;6(7):759-64. doi: 10.1016/j.cgh.2008.02.054
- Weinstock LB, Steinhoff M. Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin. J Am Acad Dermatol. 2013;68(5):875-6. doi: 10.1016/j.jaad.2012.11.038
- Drago F, De Col E, Agnoletti AF, et al. The role of small intestinal bacterial overgrowth in rosacea: A 3-year follow-up. J Am Acad Dermatol. 2016;75(3):e113-15. doi: 10.1016/j.jaad.2016.01.059
- Drago F, Ciccarese G, Herzum A, et al. The association between cigarettes smoke, small intestine bacterial overgrowth and rosacea. G Ital Dermatol Venereol. 2019;154(6):727-2. doi: 10.23736/S0392-0488.18.05919-9
- Nelson JM, Rizzo JM, Greene RK, et al. Evaluation of Helicobacter pylori and Small Intestinal Bacterial Overgrowth in Subjects With Rosacea. Cureus. 2024;16(10):e72363. doi: 10.7759/cureus.72363
- Achufusi TGO, Sharma A, Zamora EA, Manocha D. Small Intestinal Bacterial Overgrowth: Comprehensive Review of Diagnosis, Prevention, and Treatment Methods. Cureus. 2020;12(6):e8860. doi: 10.7759/cureus.8860
- Bushyhead D, Quigley EMM. Small Intestinal Bacterial Overgrowth-Pathophysiology and Its Implications for Definition and Management. Gastroenterology. 2022;163(3):593-607. doi: 10.1053/j.gastro.2022.04.002
- Daou H, Paradiso M, Hennessy K, Seminario-Vidal L. Rosacea and the Microbiome: A Systematic Review. Dermatol Ther (Heidelb). 2020;11(1):1-12. doi: 10.1007/s13555-020-00460-1
- Fernandes ES, Fernandes MA, Keeble JE. The functions of TRPA1 and TRPV1: moving away from sensory nerves. Br J Pharmacol. 2012;166(2):510-21. doi: 10.1111/j.1476-5381.2012.01851.x
- Xue Q, Pan JP, Qian D, et al. Exploring the Impact of Systemic Inflammatory Regulators on Rosacea Risk: A Bidirectional Mendelian Randomization Analysis. Clin Cosmet Investig Dermatol. 2025;18:191-200. doi: 10.2147/CCID.S495773
- Montoro-Huguet MA, Belloc B, Domínguez-Cajal M. Small and Large Intestine (I): Malabsorption of Nutrients. Nutrients. 2021;13(4):1254. doi: 10.3390/nu13041254
- Schwab VD, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15(1):53-62. doi: 10.1038/jidsymp.2011.6
- Del Rosso JQ, Brantman S, Baldwin H. Long-term inflammatory rosacea management with subantibiotic dose oral doxycycline 40 mg modified-release capsules once daily. Dermatol Ther. 2022;35(1):e15180. doi: 10.1111/dth.15180
- Sbidian E, Vicaut É, Chidiack H, et al. A Randomized-Controlled Trial of Oral Low-Dose Isotretinoin for Difficult-To-Treat Papulopustular Rosacea. J Invest Dermatol. 2016;136(6):1124-219. doi: 10.1016/j.jid.2016.01.025
- Wang FY, Chi CC. Rosacea, Germs, and Bowels: A Review on Gastrointestinal Comorbidities and Gut-Skin Axis of Rosacea. Adv Ther. 2021;38(3):1415-44. doi: 10.1007/s12325-021-01624-x
- Liao L, Su BB, Xu SP. Helicobacter pylori infection and small intestinal bacterial overgrowth: a systematic review and meta-analysis. BMC Microbiol. 2023;23(1):386. doi: 10.1186/s12866-023-03063-w
- Silva BCD, Ramos GP, Barros LL, et al. Diagnosis and treatment of small intestinal bacterial overgrowth: an official position paper from the Brazilian Federation of Gastroenterology. Arq Gastroenterol. 2025;62:e24107. doi: 10.1590/S0004-2803.24612024-107
- Ивашкин В.Т., Фомин В.В., Ткачева О.Н., и др. Синдром избыточного бактериального роста в практике врачей различных специальностей (Обзор литературы и резолюция Экспертного совета). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(2):14-34 [Ivashkin VT, Fomin VV, Tkacheva ON, et al. Small Intestinal Bacterial Overgrowth in Various Specialties of Medical Practice (Literature Review and Expert Council Resolution). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(2):14-34 (in Russian)]. doi: 10.22416/1382-4376-2024-954
- Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther. 2017;45(5):604-16. doi: 10.1111/apt.13928
- Wang J, Zhang L, Hou X. Efficacy of rifaximin in treating with small intestine bacterial overgrowth: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2021;15(12):1385-439. doi: 10.1080/17474124.2021.2005579
Supplementary files
